CDC logo, Safer Healthier People  CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us






1,2 - Oxathiolane 2,2 - dioxide

RTECS #: RP5425000

CAS #: 1120-71-4


UPDATE: May 2009 MW: 122.15 MF: C3H6O3S


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. SKIN AND EYE IRRITATION DATA:
  3. MUTATION DATA:
  4. REPRODUCTIVE EFFECTS DATA:
  5. TUMORIGENIC DATA:
  6. ACUTE TOXICITY DATA:
  7. REVIEWS:
  8. STANDARDS AND REGULATIONS:
  9. NIOSH DOCUMENTATION AND SURVEILLANCE:
  10. STATUS IN FEDERAL AGENCIES:
  11. REFERENCES:

SYNONYMS:

  1. 1,3 - Propane sultone
  2. 1 - Propanesulfonic acid - 3 - hydroxy - gamma - sultone
  3. 3 - Hydroxy - 1 - propanesulfonic acid gamma - sultone
  4. 3 - Hydroxy - 1 - propanesulphonic acid sultone
  5. Propane sultone
  1. Propane sultone (ACGIH)
  2. Propanesultone
  3. RCRA waste number U193
  4. gamma - Propane sultone


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
skin
rabbit
500 mg mild 34ZIAG -,498,1969


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE
DOSE REFERENCE
cytogenetic analysis hamster fibroblast 125 mg/L/24 hour MUREAV 48,337,1977
cytogenetic analysis hamster lung 10 mg/L ATSUDG 4,41,1980
cytogenetic analysis human lymphocyte 1 mmol/L TOLED5 28,139,1985
DNA adduct Escherichia coli 10 mol/L MUREAV 89,95,1981
DNA damage Bacillus subtilis 50 nmol/L CNREA8 41,4368,1981
DNA damage human fibroblast 5 mg/L CBINA8 22,185,1978
DNA damage human mammary gland 10 mg/L/24 hour (-enzymatic activation step) MUREAV 588,47,2005
DNA damage intraperitoneal
mouse
200 mg/kg MUREAV 467,83,2000
DNA damage intravenous
rat
31 mg/kg TCMUD8 7,175,1987
DNA inhibition skin
mouse
2 mmol/kg CNREA8 33,769,1973
DNA inhibition oral
mouse
20 gm/kg ARGEAR 51,605,1981
DNA repair Escherichia coli 500 g/disc JJIND8 62,873,1979
DNA repair other microorganisms 610 g/plate BIZNAT 95,463,1976
unscheduled DNA synthesis human fibroblast 200 mol/L/2 hour 33AQAA -,103,1976
unscheduled DNA synthesis skin
mouse
2 mmol/kg CNREA8 33,769,1973
host-mediated assay mouse
Salmonella typhimurium
12 mg/kg JJIND8 62,911,1979
mutation in microorganisms Escherichia coli 1 gm/L (-enzymatic activation step) ATXKA8 28,93,1971
mutation in microorganisms other microorganisms 1,600 mg/L (-enzymatic activation step) MOPMA3 6,667,1970
mutation in microorganisms Salmonella typhimurium 5 g/plate (+enzymatic activation step) JJIND8 62,893,1979
mutation in microorganisms Salmonella typhimurium 70 g/plate (-enzymatic activation step) PNASA6 72,5135,1975
mutation in microorganisms Serratia marcescens 25 mg/L (-enzymatic activation step) ATXKA8 30,67,1972
mutation in microorganisms Schizosaccharomyces pombe 7,900 mol/L (-enzymatic activation step) CBINA8 14,195,1976
micronucleus test intraperitoneal
mouse
18 mg/kg/48 hour- intermittent MUREAV 389,3,1997
gene conversion and mitotic recombination Saccharomyes cerevisiae 1,000 ppm JJIND8 62,901,1979
mutation in mammalian somatic cells human fibroblast 30 mg/L CNREA8 41,1620,1981
morphological transform intraperitoneal
hamster
1 gm/kg ARPAAQ 95,380,1973
morphological transform hamster kidney 80 g/L BJCAAI 37,873,1978
morphological transform hamster embryo 1 mg/L IJCNAW 19,642,1977
morphological transform human other cell types 7,500 g/L CNREA8 41,5096,1981
morphological transform mouse fibroblast 30 g/L CRNGDP 3,377,1982
morphological transform mouse embryo 50 mg/L TOLED5 9,301,1981
morphological transform rat embryo 5 mg/L JNCIAM 51,799,1973
other mutation test systems Bacillus subtilis 50 mmol/L JOBAAY 136,854,1978
other mutation test systems Salmonella typhimurium 16 mg/L MUREAV 192,239,1987
sister chromatid exchange human lymphocyte 500 mol/L TOLED5 28,139,1985


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
intravenous
rat
lowest published toxic dose: 80 mg/kg (15 day pregnant) Reproductive: Effects on embryo or fetus: Fetal death IARCCD 4,45,1973


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
intravenous
rat
lowest published toxic dose: 20 mg/kg (15 day pregnant) Tumorigenic: Carcinogenic by RTECS criteria

Reproductive: Tumorigenic effects: Transplacental tumorigenesis

Brain and Coverings: Tumors
IARCCD 4,45,1973
oral
rat
lowest published toxic dose: 7,840 mg/kg/60 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Brain and Coverings: Tumors

Skin and Appendages: Tumors
NATUAS 230,460,1971
oral
rat
toxic dose : 1,100 mg/kg/37 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Peripheral Nerve and Sensation: Peripheral nerve tumors
ZEKBAI 75,69,1970
oral
rat
toxic dose : 12 gm/kg/60 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Brain and Coverings: Tumors

Skin and Appendages: Tumors
JJIND8 67,75,1981
oral
rat
toxic dose : 13 gm/kg/32 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Brain and Coverings: Tumors

Skin and Appendages: Tumors
JJIND8 67,75,1981
subcutaneous
mouse
lowest published toxic dose: 756 mg/kg/63 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application
JNCIAM 46,143,1971
subcutaneous
rat
lowest published toxic dose: 10 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Tumorigenic: Tumors at site of application
ZEKBAI 75,69,1970
subcutaneous
rat
toxic dose : 166 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
INTSAO 66,161,1981
subcutaneous
rat
toxic dose : 559 mg/kg/17 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
INTSAO 66,161,1981
subcutaneous
rat
toxic dose : 434 mg/kg/15 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
INTSAO 66,161,1981
skin
mouse
lowest published toxic dose: 1,000 mg/kg Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Blood: Lymphoma including Hodgkin's disease
TXCYAC 6,139,1976
skin
mouse
toxic dose : 50 mg/kg/1 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application
TXAPA9 37,93,1976


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
inhalation
rat
lowest published lethal concentration: 2,140 mg/m3/6 hour Eye: Lacrimation

Vascular: Regional or general arteriolar or venous dilation

Skin and Appendages: Other: Hair
NTIS** OTS0555330
intraperitoneal
mouse
lethal dose (50 percent kill): 100 mg/kg Eye: Other eye effects

Behavioral: Somnolence (general depressed activity)

Skin and Appendages: Other: Hair
NTIS** OTS0555330
intraperitoneal
rat
lethal dose (50 percent kill): 100 mg/kg Behavioral: Convulsions or effect on seizure threshold

Lung, Thorax, or Respiration: Dyspnea

Gastrointestinal: Hypermotility, diarrhea
NTIS** OTS0555330
oral
mouse
lethal dose (50 percent kill): 400 mg/kg Behavioral: Somnolence (general depressed activity)

Behavioral: Convulsions or effect on seizure threshold

Skin and Appendages: Other: Hair
NTIS** OTS0555330
oral
rat
lethal dose (50 percent kill): 100 mg/kg Behavioral: Convulsions or effect on seizure threshold

Lung, Thorax, or Respiration: Dyspnea

Gastrointestinal: Hypermotility, diarrhea
NTIS** OTS0555330
subcutaneous
rat
lethal dose (50 percent kill): 135 mg/kg N/R ZEKBAI 75,69,1970
skin
mouse
lowest published lethal dose: 1,000 gm/kg N/R TXCYAC 6,139,1976


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
N/R
N/R N/R N/R


REVIEWS:

ORGANIZATION STANDARD
REFERENCE

American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value Control as low as possible DTLVS* TLV/BEI,2007
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value Confirmed animal carcinogen DTLVS* TLV/BEI,2007
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 4,253,1974
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 71,1095,1999
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 4,253,1974
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 71,1095,1999
International Agency for Research on Cancer (IARC) Cancer Review Group 2B IMEMDT 71,1095,1999
TOXICOLOGY REVIEW
TOLED5 151,251,2004
TOXICOLOGY REVIEW
MUREAV 627,10,2007
TOXICOLOGY REVIEW
MUREAV 584,1,2005


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE

Occupational Exposure Limit - AUSTRALIA Carcinogen, JUL2008
Occupational Exposure Limit - SWEDEN Group B Carcinogen, JUN2005
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value;

Confirmed animal carcinogen
Occupational Exposure Limit IN SINGAPORE, VIETNAM American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value
Confirmed animal carcinogen


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE

National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO PROPANE SULTONE-air Carcinogen lowest feasible concentration NIOSH* DHHS #92-100,1992


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE

EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-RLV F344 rat embryo
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE; Host-mediated assay
EPA GENETOX PROGRAM 1988, Positive: E coli polA without S9; Histidine reversion-Ames test
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae gene conversion; S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Positive: S pombe-reversion
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro SCE-nonhuman
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro UDS-human fibroblast
EPA GENETOX PROGRAM 1988, Inconclusive: SHE-clonal assay
EPA TSCA Section 8(b) CHEMICAL INVENTORY
Used as an intermediate in the preparation of other compounds
EPA TSCA Section 8(d) unpublished health/safety studies
On EPA IRIS database
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NTP 11th Report on Carcinogens,2004:Reasonably anticipated to be a human carcinogen


REFERENCES:

CODEN
REFERENCE

33AQAA "Biology of Radiation Carcinogenesis, Symposium, 1975," Yuhas, J.M., et al., eds., New York, Raven Press, 1976
34ZIAG "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969
ARGEAR Archiv fuer Geschwulstforschung. (VEB Verlag Volk und Gesundheit Neue Gruenstr. 18, Berlin DDR-1020, Ger. Dem. Rep.) V.1- 1949-
ARPAAQ Archives of Pathology. (Chicago, IL) V.5(3)-50(3), 1928-50; V.70-99, 1960-75. For publisher information, see APLMAS.
ATSUDG Archives of Toxicology, Supplement. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) No.1- 1978-
ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher information, see ARTODN.
BIZNAT Biologisches Zentralblatt. (VEB Georg Thieme, Postfach 946, Leipzig DDR-7010, Ger. Dem. Rep.) V.1- 1881-
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
CBINA8 Chemico-Biological Interactions. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1969-
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996
IARCCD IARC Scientific Publications. (Geneva, Switzerland) No.1-26, 1971-78. For publisher information, see IAPUDO.
IJCNAW International Journal of Cancer. (International Union Against Cancer, 3 rue du Conseil- General, 1205 Geneva, Switzerland) V.1- 1966-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
INTSAO International Surgery. (International College of Surgeons, 1516 N. Lake Shore Dr., Chicago, IL 60610) V.45- 1966-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JOBAAY Journal of Bacteriology. (American Soc. for Microbiology, 1913 I St., NW, Washington, DC 20006) V.1- 1916-
MOPMA3 Molecular Pharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1965-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869-
NIOSH* National Institute of Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda.
NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information.
PNASA6 Proceedings of the National Academy of Sciences of the United States of America. (National Academy of Sciences, Printing & Pub. Office, 2101 Constitution Ave., Washington, DC 20418) V.1- 1915-
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980-
TOLED5 Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977-
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-
ZEKBAI Zeitschrift fuer Krebsforschung. (Berlin, Fed. Rep. Ger.) V.1-75, 1903-71. For publisher information, see JCROD7.

Used as an intermediate in the preparation of other compounds

RTECS Compound Description:
   Tumorigen
   Mutagen
   Reproductive Effector
   Human Data
   Primary Irritant

Click Here for Additional Information about RTECS

NIOSH Home |  NIOSH Search  |  Site Index  |  Topic List |  Contact Us